logo
More research needed on wildfire smoke toxicity, scientists say as they warn of pollution 'time bomb'

More research needed on wildfire smoke toxicity, scientists say as they warn of pollution 'time bomb'

CBC24-07-2025
Wildfire smoke in Manitoba could be even more toxic than usual and more research needs to be done on the pollutants being released into the air, according to scientists.
The fires may be releasing pollution stored in the province's soil for millennia, including toxic chemicals from more than a century of resource exploitation in the north, said Colin McCarter, Canada Research Chair of Climate and Environmental Change.
Peatlands cover about one-third of the province and the boggy wetland is a critical carbon storehouse and even acts as a natural fire barrier, but climate change is increasingly putting them at risk.
As the landscapes dry out and become more susceptible to the flames, a "pollution time bomb" is potentially set to go off, McCarter said.
Peatlands are "also regionally really important landscape stores or sinks of toxic metals," he said. "Toxic metals can range from everyday things that we think about [like] copper … [to] lead, arsenic, mercury — all these things that are associated with quite poor human health outcomes."
McCarter said peatlands are able to sequester more of these toxic metals than other ecosystems, and that it's easy to find peatland-rich areas in Canada which are near places where there's been historical industrial activity and resource extraction, including Flin Flon.
A fire that forced the evacuation of the city about 760 kilometres northwest of Winnipeg, in late May was about 347,105 hectares large this week, making it the biggest active wildfire in the province.
The community's last mine closed in 2022. Its copper-zinc smelter — which had been operating since the 1920s — shut down in 2010.
At one point, the Flin Flon smelter emitted more than 200,000 tonnes of sulfur-dioxide a year. Studies done over the past three decades have found elevated levels of mercury and other trace metals in sediment cores, soil humus, plants and peat.
Environment and Climate Change Canada said that while it was operational, the smelter was the largest single source of atmospheric mercury emissions in the country.
"I can name probably half a dozen other sites across Canada where you have this kind of … landscape-level pollution from this historical industrial contamination in the boreal, which is a fire ecosystem," McCarter said, mentioning Thompson which is about 15 kilometres southwest of another wildfire.
"It's a fire-adapted ecosystem and … normally burns."
But McCarter said the level of toxicity of what may be released depends on several factors, including the temperature of the fire, the type of peatland and climate conditions.
"Trying to make that link there … from what's in the peatlands to what is the risk is still a very active part of my research," he said.
"We're starting to put some of those ideas to experiments, but we're still missing those linkages to really make these predictions about risk."
'We need studies'
Michael Schindler is a professor with the University of Manitoba's department of earth sciences, and has previously done research on how pollutants mix with wildfire smoke.
"Contaminants at Flin Flon are mainly lead, zinc, mercury," Schindler said, adding that selenium is an issue. The province limited consumption of fish at a nearby lake last year due to elevated selenium levels, which were likely a result of mine wastewater over the past century.
Schindler said contaminants that couldn't normally be inhaled get attached to the finer particles in wildfire smoke, allowing them to get into the lungs.
The particles "are literally the Trojan horse," he said. The smoke's "health effects are much greater."
Many of the metal particles released by a smelter are "pretty locked up," Schindler said. "But some of them are already mobile and those could theoretically … be volatilized and attach, especially mercury which is a really volatile element. Selenium, also."
Smoke from Canada's wildfires spread across North America and even crossed the Atlantic Ocean this summer.
"It's huge amounts of wildfire smoke and you get those metals coming in … but it will delude over a long distance," Schindler said.
The professor said he's more worried about the smoke mixing in with urban pollutants downstream, coming from sources like "literally every diesel engine."
The toxic metals theoretically "may affect just the people in Flin Flon, but we need studies," Schindler said.
"Is the population around Flin Flon more affected by the wildfire smoke in terms of health issues later on than a community where there has not been mining or smelting? I think people in Manitoba should know about this."
Dave Price has lived in Flin Flon since the 1970s. A former geologist, he was among a group of volunteers who worked to rehabilitate land around the city that had been left barren because of increased acidity caused by the smelter's emissions for more than a decade. The project wrapped up in 2016.
Price was among the 5,000 residents who were allowed to return to the community last month.
"It was a very hot fire as far as I understand it. That is to say, the trees were burned down to the roots and the burning continued into the peat underneath, and the peat underneath did contain these metals," he said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

Globe and Mail

time11 minutes ago

  • Globe and Mail

Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN), today released a letter to stockholders. Dear Fellow Stockholders, Tevogen has rapidly evolved from a biotechnology innovator into a dynamic enterprise expanding into artificial intelligence through Our mission remains steadfast: delivering clinically impactful, economically accessible therapies by leveraging cutting-edge science and technology. Tevogen has become a recognized name for its business philosophy of social responsibility, patient affordability and cost efficiency. In under five years, we validated our proprietary ExacTcell™ platform, completed successful proof-of-concept clinical trial of the platforms first product, established drug discovery R&D center — currently in the process of establishing our own GMP cell manufacturing facility, expanded corporate infrastructure, built a robust intellectual property portfolio, and established one of the pioneering AI initiatives in the industry — assets of significant value, while maintaining 74% insider equity ownership. With the successful launch of our proprietary AI-driven PredicTcell™ platform, we've significantly enhanced target discovery efficiency. Strategic partnerships with global technology leaders, such as Microsoft and Databricks, have accelerated our progress. Recent patent filings further secure our intellectual property in AI-driven predictive modeling, positioning us at the forefront of innovation. Importantly, Tevogen Bio is well capitalized, having access to necessary funding we may require to fully execute our current growth strategy, including the accelerated development of While the sector faces significant challenges, our company continues to grow, underscoring the foundational strength of our company. We deeply appreciate your continued support as we work toward our vision of transforming healthcare through democratizing access. It feels good to be part of this growth story and am grateful to my colleagues at Tevogen for their exceptional expertise, dedication, and, above all, their compassion for others. Sincerely, Ryan Saadi, MD, MPH Founder and CEO, Tevogen Bio Recent Announcements Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation Forward-Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store